<DOC>
	<DOC>NCT01693679</DOC>
	<brief_summary>• To estimate renoprotective efficacy of Telbivudine treated patients with HBV-related liver cirrhosis.</brief_summary>
	<brief_title>Telbivudine Renoprotective Effect in Patients With HBV-related Liver Cirrhosis</brief_title>
	<detailed_description />
	<mesh_term>Fibrosis</mesh_term>
	<mesh_term>Liver Cirrhosis</mesh_term>
	<mesh_term>Adefovir</mesh_term>
	<mesh_term>Adefovir dipivoxil</mesh_term>
	<mesh_term>Telbivudine</mesh_term>
	<mesh_term>Lamivudine</mesh_term>
	<criteria>Subjects eligible for enrolment in the study must meet all of the following criteria: Aged between 1875 years (inclusive). Male or female. Subjects with positive HBsAg for more than 6 months and antiHBs negative regardless of HBeAg status , HBV DNA ≥2×103 IU/ml Subjects with HBVrelated liver cirrhosis, including compensated cirrhosis and decompensated, but only ChildPugh A or B. The ablility to understand and sign a written informed consent prior to any study related procedure and comply with the requirements of the study. Subjects meeting any of the following criteria must not be enrolled in the study Subjects with nonHBV cirrhosis Coinfection with HAV/HCV/HDV/ HIV Subjects who take nucleosides within 6 months Kidney injury due to nonHBV factors Inability to comply with study requirements as determined by the study investigator Patients with very low GFR, who may need dialysis or renal transplantation</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>September 2012</verification_date>
	<keyword>Tebivudine eGFR non-Tebivudine</keyword>
</DOC>